Key Points
- CEO Helen Torley sold 16,569 shares on Dec. 1 for $1,141,935.48 (avg $68.92), reducing her stake by 2.28%; this follows four earlier sales this year (totaling 80,000 shares), bringing the year-to-date insider disposals to about 96,569 shares.
- Halozyme reported a strong quarter—EPS $1.72 vs. $1.63 expected and revenue $354.26M vs. $339.18M expected—with revenue up 22.1% year-over-year and a net margin of 47.28%.
- The stock is trading down (opened $68.10) with a one-year range of $46.26–$79.50, a market cap of ~$8.01B, and a consensus analyst view of a "Moderate Buy" with a $75.10 target.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Bernadette Connaughton sold 829 shares of the firm's stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $71.60, for a total value of $59,356.40. Following the completion of the sale, the director directly owned 42,123 shares in the company, valued at approximately $3,016,006.80. The trade was a 1.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Bernadette Connaughton also recently made the following trade(s):
- On Monday, November 10th, Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $68.48, for a total transaction of $136,960.00.
- On Wednesday, October 1st, Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $75.24, for a total transaction of $150,480.00.
- On Tuesday, September 2nd, Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00.
Halozyme Therapeutics Stock Performance
NASDAQ:HALO opened at $68.10 on Tuesday. The company has a market cap of $8.01 billion, a P/E ratio of 15.58, a P/E/G ratio of 0.35 and a beta of 1.18. The firm's 50 day moving average is $69.05 and its two-hundred day moving average is $64.09. Halozyme Therapeutics, Inc. has a fifty-two week low of $46.26 and a fifty-two week high of $79.50. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $354.26 million during the quarter, compared to analysts' expectations of $339.18 million. During the same period in the previous year, the company earned $1.27 EPS. The business's quarterly revenue was up 22.1% compared to the same quarter last year. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on the company. Benchmark raised their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. HC Wainwright reaffirmed a "buy" rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research report on Friday. Leerink Partners upgraded shares of Halozyme Therapeutics from an "underperform" rating to a "market perform" rating and set a $70.00 price objective for the company in a research note on Tuesday, October 14th. JMP Securities raised their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a research note on Wednesday, August 6th. Finally, Citizens Jmp upped their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a "market outperform" rating in a research report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $75.10.
Read Our Latest Stock Analysis on HALO
Institutional Trading of Halozyme Therapeutics
A number of hedge funds have recently made changes to their positions in HALO. Root Financial Partners LLC bought a new position in Halozyme Therapeutics during the 3rd quarter valued at $25,000. Larson Financial Group LLC increased its position in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 343 shares during the last quarter. Richardson Financial Services Inc. raised its stake in shares of Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 198 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Halozyme Therapeutics during the first quarter worth about $32,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in Halozyme Therapeutics in the second quarter worth about $32,000. Institutional investors and hedge funds own 97.79% of the company's stock.
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
